Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Vioxx Pain Subsides

Executive Summary

An Atlantic City, N.J. state court jury verdict clears Merck of allegations the drug maker failed to properly warn patients of risks associated with the use of Vioxx (rofecoxib). "We presented a case that was solidly based on scientific evidence," Merck said. The case, Humeston v. Merck, is the second Vioxx case to reach trial; an Angleton, Texas jury found Merck liable for the death of Robert Ernst in August, awarding his widow $253.5 mil. in damages (1"The Pink Sheet" Aug. 29, 2005, p. 3)...

You may also be interested in...



Merck Reconsiders Legal Strategy: Will Settlements Ease Vioxx Pain?

Merck may opt to settle select Vioxx liability lawsuits in cases where the evidence is clearly in favor of the plaintiff in the wake of the Texas jury verdict against the drug maker

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel